ReviewCurrent diabetes reports2010
Best strategies for hypertension management in type 2 diabetes and obesity.
Review in Current diabetes reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- 7th Brazilian Guideline of Arterial Hypertension: Chapter 10 - Hypertension in Children and AdolescentsArquivos brasileiros de cardiologia · 2016Guideline
- Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery.Gland surgery · 2020Review
- Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle.Journal of visualized experiments : JoVE · 2017Article
- Rational use of antihypertensive medications in children.Pediatric nephrology (Berlin, Germany) · 2014Review
- Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.Life sciences · 2013Review
- Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2013Review
- Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.American journal of physiology. Renal physiology · 2012Article
- Cardiac insulin resistance and microRNA modulators.Experimental diabetes research · 2012Review
- Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.American journal of physiology. Regulatory, integrative and comparative physiology · 2011Review
- The role of antiplatelets in hypertension and diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance, dyslipidemia, hypertension, obesity, cardiovascular disease, and chronic kidney disease cluster together, and the incidence of all of these disease states is increasing throughout the world. Current strategies for hypertension management-including the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, and thiazide diuretics-are effective for most patients. However, as the incidence of hypertension increases in this target population, so does that of resistant hypertension. As such, significant research and effort must be put forth to bring blood pressure to goal and delay or prevent target organ damage. Such efforts should frequently include a dihydropyridine calcium channel blocker such as amlodipine. Other agents that are currently underused in this population for the treatment of resistant hypertension include nebivolol, carvedilol, aliskiren, and aldosterone antagonists. Finally, significant potential is seen for darusentan, an endothelin antagonist, if it comes to market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.